Form 4: BioLargo Director Linda Park Acquires Shares Through Option Grant
SEC Form 4 Filing
Director Linda Park receives options to purchase 81,522 shares of BioLargo, Inc. stock as compensation for board service.
Summary
- Linda Park, a director of BioLargo, Inc. (BLGO), acquired options to purchase 81,522 shares of common stock on October 2, 2024.
- The options were granted at an exercise price of $0.23 per share.
- These options were issued as payment for $18,750 in fees for board services during the most recent quarterly period, according to the company's 2024 Equity Incentive Plan.
- Following the transaction, Ms. Park directly owns options for 794,333 shares.
- A Limited Power of Attorney was granted to John R. Browning to handle Section 16 reporting obligations on behalf of Linda Park.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction (option grant) as part of director compensation, which is generally viewed neutrally to positively as it aligns interests. There are no indications of negative news or concerns.
Positives
- The option grant aligns director compensation with company performance.
- The equity incentive plan encourages directors to act in the best interest of shareholders.
Future Outlook
NA
Industry Context
Option grants to directors are a common practice in publicly traded companies to align their interests with those of shareholders. The size and terms of the grant are typical for a company of BioLargo's size and stage.
Comparison to Industry Standards
- Director compensation packages, including option grants, vary widely across industries and company sizes.
- Comparing BioLargo's director compensation to similar small-cap companies in the environmental technology sector would provide a more accurate benchmark.
- Companies like OriginClear and AquaVenture Holdings also utilize equity-based compensation for their board members.
Stakeholder Impact
- The option grant could potentially dilute existing shareholders if the options are exercised.
- The grant incentivizes the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Date of Limited Power of Attorney execution. |
| 2024-09-30 | Date exercisable for the option to purchase common stock. |
| 2024-09-30 | Date of expiration for the option to purchase common stock. |
| 2024-10-02 | Date of transaction (option grant). |
| 2034-09-30 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.